<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="pmed.1003092.t001" orientation="portrait" position="float">
 <object-id pub-id-type="doi">10.1371/journal.pmed.1003092.t001</object-id>
 <label>Table 1</label>
 <caption>
  <title>Four pathways to obtain marketing authorization for medicines in the EU.</title>
 </caption>
 <alternatives>
  <graphic id="pmed.1003092.t001g" xlink:href="pmed.1003092.t001" xmlns:xlink="http://www.w3.org/1999/xlink"/>
  <table frame="hsides" rules="groups">
   <colgroup span="1">
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
   </colgroup>
   <thead>
    <tr>
     <th align="center" rowspan="1" colspan="1">Pathway</th>
     <th align="center" rowspan="1" colspan="1">Process</th>
     <th align="center" rowspan="1" colspan="1">Notes on use</th>
    </tr>
   </thead>
   <tbody>
    <tr>
     <td align="left" rowspan="1" colspan="1">Centralized procedure</td>
     <td align="left" rowspan="1" colspan="1">Manufacturer submits application directly to the EMA. The CHMP then draws on scientific expertise from EU member states (which collectively contribute to the scientific evaluation of new products) to determine whether the medicine should be authorized.</td>
     <td align="left" rowspan="1" colspan="1">Mandatory for many new substances</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">Decentralized procedure</td>
     <td align="left" rowspan="1" colspan="1">One EU member state performs the initial evaluation of a medicine and issues a draft assessment report, after which other member states have the opportunity to ask questions and raise objections.</td>
     <td align="left" rowspan="2" colspan="1">Most generics in the EU are approved via these procedures</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">Mutual recognition procedure</td>
     <td align="left" rowspan="1" colspan="1">Similar to the decentralized process; if a medicine has already been approved in at least 1 EU member state, and its manufacturer is seeking approval in at least 1 other member state, the member state that has already authorized the medicine issues a draft assessment report. Afterwards, other member states have the opportunity to ask questions and raise objections.</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">National procedure</td>
     <td align="left" rowspan="1" colspan="1">A medicine is approved in only a single EU member state and no interaction with or recognition by other member states occurs.</td>
     <td align="left" rowspan="1" colspan="1">Rarely used</td>
    </tr>
   </tbody>
  </table>
 </alternatives>
 <table-wrap-foot>
  <fn id="t001fn001">
   <p>
    <bold>Abbreviations:</bold> CHMP, Committee for Medicinal Products for Human Use; EMA, European Medicines Agency; EU, European Union
   </p>
  </fn>
 </table-wrap-foot>
</table-wrap>
